Volume 3, Number 5, Supplement 1 (May 2006)

Controversies in Patient Management

2

Switching from tamoxifen to exemestane in localized breast cancer: four representative case studies

Charles L. Shapiro, MD
Shannon Puhalla, MD

The Comprehensive Breast Health Services, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Medical Center, Columbus, OH

Lisa E. Sokolowicz, MD
William J. Gradishar, MD

Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Alejandro Calvo, MD

Medical Oncology Hematology Associates, Inc, Centerville, OH

Victor G. Vogel, MD, MHS

Magee-Womens Hospital/University of Pittsburgh Cancer Institute Biochemoprevention Program, University of Pittsburgh School of Medicine, Pittsburgh, PA

Many postmenopausal women with early breast cancer receive adjuvant tamoxifen therapy to reduce their risk of relapse. Recent clinical trials show that third-generation aromatase inhibitors, given either as initial adjuvant therapy or after treatment with tamoxifen, produce better overall and disease-free survival rates, less risk of local or distant recurrence, and improved safety and tolerability, compared with tamoxifen alone. Aromatase inhibitors block the synthesis of estrogen by aromatase, whereas tamoxifen, an antiestrogen, blocks the binding of estrogen to its receptor. The American Society of Clinical Oncology currently recommends using an aromatase inhibitor in the adjuvant treatment of postmenopausal women with early estrogen receptor–positive breast cancer. Questions regarding the optimal use of aromatase inhibitors remain. The cases presented here are instructive with regard to deciding whether to make the switch to exemestane after tamoxifen.

full text

132 kb

Financial support has been provided by Pfizer Inc

© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.